Home Featured Page 293

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in...

Red Light Holland’s iMicro Digital Care App Launches Virtual Telecounseling with...

Lobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to...

Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and...

BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s...

Nova Mentis Launches Autism Microbiome Study in the United States

Awakn Announces Exclusive License Deal with the University of Exeter to...

Can Psilocybin and LSD Relieve Existential Suffering?

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.